LATANOPROSTENE BUNOD
| Brand name | VYZULTA |
|---|---|
| Active ingredient | LATANOPROSTENE BUNOD |
| Strength | 0.024% |
| Dosage form | SOLUTION/DROPS |
| Route | OPHTHALMIC |
| Modality | Small molecule |
| FDA approval | November 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 8058467 | February 2029 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.